Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
about
Quantifying cardiometabolic risk using modifiable non-self-reported risk factorsDiabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survivalInsulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical ExperienceDifferential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr-/- miceAssociation of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study.Diabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?Glycated hemoglobin independently predicts stroke recurrence within one year after acute first-ever non-cardioembolic strokes onset in A Chinese cohort study.Administration of Danhong Injection to diabetic db/db mice inhibits the development of diabetic retinopathy and nephropathy.Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments.Retinal vascular caliber as a biomarker for diabetes microvascular complications.The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial.The Hispanic paradox and predictors of mortality in an aging biethnic cohort of Mexican Americans and European Americans: the san antonio longitudinal study of aging.Exposure to high or low glucose levels accelerates the appearance of markers of endothelial cell senescence and induces dysregulation of nitric oxide synthaseAssociation of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trialAdherence to therapies in patients with type 2 diabetes.Role of metabolic environment on nitric oxide mediated inhibition of neointimal hyperplasia in type 1 and type 2 diabetes.Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics.Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes.Small vessel disease and memory loss: what the clinician needs to know to preserve patients' brain health.The clinical implications of recent studies on the structure and function of the retinal microvasculature in diabetes.Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.Association between microfibrillar-associated protein 4 (MFAP4) and micro- and macrovascular complications in long-term type 1 diabetes mellitus.Beneficial Effect of Glucose Control on Atherosclerosis Progression in Diabetic ApoE(-/-) Mice: Shown by Rage Directed Imaging.Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.Pharmacological Effects and Pharmacokinetic Properties of a Dual-Function Peptide 5rolGLP-HV.NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice.Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
P2860
Q24169777-26697EA6-457F-4BCA-943A-EE2EE0C6D57CQ26827620-177218C4-BE28-4166-9D1C-4A6FBF463BA4Q28085428-20C773C9-ECB9-4851-BFC0-46E5DA2FD68EQ28486194-E0A894BE-A47C-48EE-B60D-D3B3DB02F893Q34503055-E09AD6B3-2A35-4437-9D95-F23319EF233EQ34612834-68DFF2EF-27C3-47D3-A4F9-C968E5372F59Q35044001-7D8D5EEF-AF10-4452-AD33-5AFD28D94C38Q35711564-8AC2C12D-E03A-477E-BCB0-010AEE217EFBQ36597980-046DF880-36BE-4976-8327-DA1BAA935BFFQ36629567-851EB21A-4C46-4D02-946E-2D334CB997C0Q37170289-0B2850F1-B394-46FC-A224-3693EC48C472Q37171348-350D457B-99AC-4743-822C-7D086AE6F777Q37270908-E9973307-6A99-403A-907A-592027DED094Q37277912-91FA1A48-2A1B-4F47-A500-563963F33D35Q37468440-87C17BC7-A46C-438D-A756-FDA3E35CCCF5Q37567611-C4AC5201-8578-4F5D-82B8-A2CCCED7F4A8Q38004987-7D5D3E82-903B-4D6F-A90E-0B78EFEB0BCEQ38073629-BFFABDED-01CF-4D6C-9BD9-3B3CB12A64E1Q38150763-DB3CE27D-AF9F-408F-A675-042396F0A34AQ38351156-A23E6C17-306E-4507-9BDA-0BF8EC8EAA8DQ38712728-023478C3-5EA0-4878-93D9-2DED165BB1D4Q39048316-68AC34AF-65D3-448B-9A26-C074EBAC90A6Q39199900-4B6FFC97-2D2F-45F5-82B5-0AA7156A147FQ49689988-9BBE6AEB-D975-49AE-92F7-42ECA2223960Q50489100-7327A904-9CEC-4C66-BF1C-8EC6082D1CC9Q55398039-7CCE8B58-95FE-4B32-B4B9-479D9248C566Q57813255-6A266D3B-149A-41FD-A0D7-83DA16A584AF
P2860
Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Does aggressive glycemic contr ...... rom ACCORD, ADVANCE, and VADT.
@en
Does aggressive glycemic contr ...... rom ACCORD, ADVANCE, and VADT.
@nl
type
label
Does aggressive glycemic contr ...... rom ACCORD, ADVANCE, and VADT.
@en
Does aggressive glycemic contr ...... rom ACCORD, ADVANCE, and VADT.
@nl
prefLabel
Does aggressive glycemic contr ...... rom ACCORD, ADVANCE, and VADT.
@en
Does aggressive glycemic contr ...... rom ACCORD, ADVANCE, and VADT.
@nl
P2093
P2860
P1476
Does aggressive glycemic contr ...... rom ACCORD, ADVANCE, and VADT.
@en
P2093
Kalyani Raravikar
Nalurporn Chokrungvaranon
Peter D Reaven
Toni Terry
P2860
P2888
P356
10.1007/S11886-011-0238-6
P577
2012-02-01T00:00:00Z